Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders

Key Findings:  The reviewers conclude that cannabinoids, in particular CBD, improves symptoms associated with common co-morbidities in ASD's. In addition, cannabinoid-based therapeutics is associated with low adverse effects and a reduction in concomitant medication.

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  Portugal

Year of Pub:  2022

Cannabinoids Studied:  Cannabidiol (CBD), Cannabinoid (unspecified)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III